×
About 434 results

ALLMedicine™ Facioscapulohumeral Dystrophy Center

Research & Reviews  217 results

Phase 1 Clinical Trial of Losmapimod in Facioscapulohumeral Dystrophy (FSHD): Safety, T...
https://doi.org/10.1111/bcp.14884
British Journal of Clinical Pharmacology; Mellion ML, Ronco L et. al.

May 1st, 2021 - Evaluate safety, tolerability, pharmacokinetics (PK), and target engagement (TE) of losmapimod in blood and muscle in facioscapulohumeral dystrophy (FSHD). This study included Part A: 10 healthy volunteers (HVs) randomized to single oral doses of ...

CLIA Laboratory Testing for Facioscapulohumeral Dystrophy: A Retrospective Analysis.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8055331
Neurology Rieken A, Bossler AD et. al.

Jan 14th, 2021 - To summarize facioscapulohumeral muscular dystrophy (FSHD) diagnostic testing results from the University of Iowa Molecular Pathology Laboratory. All FSHD tests performed in the diagnostic laboratory from January 2015 to July 2019 were retrospecti...

Chromosome 10q-linked FSHD identifies DUX4 as principal disease gene.
https://doi.org/10.1136/jmedgenet-2020-107041
Journal of Medical Genetics; Lemmers RJLF, van der Vliet PJ et. al.

Jan 13th, 2021 - Facioscapulohumeral dystrophy (FSHD) is an inherited muscular dystrophy clinically characterised by muscle weakness starting with the facial and upper extremity muscles. A disease model has been developed that postulates that failure in somatic re...

Motion sensor-acquired reachable workspace correlates with patient-reported upper extre...
https://doi.org/10.1002/mus.27123
Muscle & Nerve; Hatch MN, Kurillo G et. al.

Nov 20th, 2020 - This study examines the correlation, and clinical meaningfulness, between reachable workspace outcome and reported activities of daily living (ADL) function of individuals with facioscapulohumeral dystrophy (FSHD). Twenty-one FSHD subjects with va...

Effects of dexmedetomidine as a perineural adjuvant for femoral nerve block: A systemat...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7571703
PloS One; Zhao ZF, Du L et. al.

Oct 19th, 2020 - Facioscapulohumeral dystrophy (FSHD) is characterized by a loss of repressive epigenetic marks leading to the aberrant expression of the DUX4 transcription factor. In muscle, DUX4 acts as a poison protein though the induction of multiple downstrea...

see more →

Clinicaltrials.gov  217 results

Phase 1 Clinical Trial of Losmapimod in Facioscapulohumeral Dystrophy (FSHD): Safety, T...
https://doi.org/10.1111/bcp.14884
British Journal of Clinical Pharmacology; Mellion ML, Ronco L et. al.

May 1st, 2021 - Evaluate safety, tolerability, pharmacokinetics (PK), and target engagement (TE) of losmapimod in blood and muscle in facioscapulohumeral dystrophy (FSHD). This study included Part A: 10 healthy volunteers (HVs) randomized to single oral doses of ...

CLIA Laboratory Testing for Facioscapulohumeral Dystrophy: A Retrospective Analysis.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8055331
Neurology Rieken A, Bossler AD et. al.

Jan 14th, 2021 - To summarize facioscapulohumeral muscular dystrophy (FSHD) diagnostic testing results from the University of Iowa Molecular Pathology Laboratory. All FSHD tests performed in the diagnostic laboratory from January 2015 to July 2019 were retrospecti...

Chromosome 10q-linked FSHD identifies DUX4 as principal disease gene.
https://doi.org/10.1136/jmedgenet-2020-107041
Journal of Medical Genetics; Lemmers RJLF, van der Vliet PJ et. al.

Jan 13th, 2021 - Facioscapulohumeral dystrophy (FSHD) is an inherited muscular dystrophy clinically characterised by muscle weakness starting with the facial and upper extremity muscles. A disease model has been developed that postulates that failure in somatic re...

Motion sensor-acquired reachable workspace correlates with patient-reported upper extre...
https://doi.org/10.1002/mus.27123
Muscle & Nerve; Hatch MN, Kurillo G et. al.

Nov 20th, 2020 - This study examines the correlation, and clinical meaningfulness, between reachable workspace outcome and reported activities of daily living (ADL) function of individuals with facioscapulohumeral dystrophy (FSHD). Twenty-one FSHD subjects with va...

Effects of dexmedetomidine as a perineural adjuvant for femoral nerve block: A systemat...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7571703
PloS One; Zhao ZF, Du L et. al.

Oct 19th, 2020 - Facioscapulohumeral dystrophy (FSHD) is characterized by a loss of repressive epigenetic marks leading to the aberrant expression of the DUX4 transcription factor. In muscle, DUX4 acts as a poison protein though the induction of multiple downstrea...

see more →